CA2309154A1 - Substituted porphyrins - Google Patents

Substituted porphyrins Download PDF

Info

Publication number
CA2309154A1
CA2309154A1 CA002309154A CA2309154A CA2309154A1 CA 2309154 A1 CA2309154 A1 CA 2309154A1 CA 002309154 A CA002309154 A CA 002309154A CA 2309154 A CA2309154 A CA 2309154A CA 2309154 A1 CA2309154 A1 CA 2309154A1
Authority
CA
Canada
Prior art keywords
compound
alpha
group
independently
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002309154A
Other languages
French (fr)
Other versions
CA2309154C (en
Inventor
Irwin Fridovich
Ines Batinic-Haberle
James D. Crapo
Brian J. Day
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Jewish Health
Duke University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2309154A1 publication Critical patent/CA2309154A1/en
Application granted granted Critical
Publication of CA2309154C publication Critical patent/CA2309154C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Abstract

The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.

Claims (27)

1. A compound of formula or pharmaceutically acceptable salt thereof, wherein each R is, independently, a C1-C8 alkyl group, and each P is, independently, an electron withdrawing group or hydrogen, wherein when each R is methyl and each P is hydrogen, said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.
2. The compound according to claim 1 where each R
is independently a C1-C4 alkyl group.
3. The compound according to claim 2 wherein each R is, independently, a methyl, ethyl or isopropyl group.
4. The compound according to claim 3 wherein each R is, independently, a methyl or an ethyl group.
5. The compound according to claim 1 wherein each P is, independently, hydrogen or an electron withdrawing group selected from the group consisting of -NO2, a halogen, a nitrile, a vinyl group and a formyl group.
6. The compound according to claim 1 wherein at least one P is a halogen.
7. The compound according to claim 1 wherein one or two P's are formyl groups and the remaining P's are hydrogen.
8. The compound according to claim 1 wherein one P is a formyl group and the remaining P's are hydrogen.
9. The compound according to claim 1 wherein one or two P's are -NO2 and the remaining P's are hydrogen.
10. The compound according to any one of claims 1-9 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.
11. The compound according to claim 10 wherein said compound is complexed with manganese.
12. The compound according to claim 1 wherein each R is a methyl or ethyl group, each P is a hydrogen, and said compound is complexed with manganese.
13. The compound according to claim 1 wherein each R is a methyl or ethyl group, at least one P is Br and the remaining P's are hydrogen and said compound is complexed with manganese.
14. The compound according to claim 1 wherein said compound is a mixture of atropoisomers .alpha..alpha..alpha..alpha., .alpha..alpha..alpha..beta., .alpha..alpha..beta..beta.
and .alpha..beta..alpha..beta..
15. The compound according to claim 1 wherein said compound is a mixture of .alpha..alpha..alpha..beta. and .alpha..alpha..alpha..alpha. atropoisomers.
16. A method of protecting cells from oxidant-induced toxicity comprising contacting said cells with a protective amount of a compound of formula or pharmaceutically acceptable salt thereof, wherein each R is, independently, a C1-C8 alkyl group, and each P is, independently, an electron withdrawing group or hydrogen.
17. The method according to claim 16 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.
18. The method according to claim 16 wherein said cells are mammalian cells.
19. A method of treating a pathological condition of a patient resulting from oxidant-induced toxicity comprising administering to said patient an effective amount of a compound of formula or pharmaceutically acceptable salt thereof, wherein each R is, independently, a C1-C8 alkyl group, and each P is, independently, an electron withdrawing group or hydrogen.
20. The method according to claim 19 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.
21. A method of treating a pathological condition of a patient resulting from degradation of NO~ or a biologically active form thereof, comprising administering to said patient an effective amount of a compound of formula or pharmaceutically acceptable salt thereof, wherein each R is, independently, a C1-C8 alkyl group, and each P is, independently, an electron withdrawing group or hydrogen.
22. The method according to claim 21 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.
23. A method of treating a patient for inflammatory lung disease comprising administering to said patient an effective amount of a compound of formula or pharmaceutically acceptable salt thereof, wherein each R is, independently, a C1-C8 alkyl group, and each P is, independently, an electron withdrawing group or hydrogen.
24. The method according to claim 23 wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.
25. The method according to claim 24 wherein said metal is manganese.
26. The method according to claim 23 wherein said inflammatory lung disease is a hyper-reactive airway disease.
27. The method according to claim 23 wherein said inflammatory lung disease is asthma.
CA2309154A 1997-11-03 1998-11-03 Substituted porphyrins Expired - Lifetime CA2309154C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6411697P 1997-11-03 1997-11-03
US60/064,116 1997-11-03
PCT/US1998/023287 WO1999023097A1 (en) 1997-11-03 1998-11-03 Substituted porphyrins

Publications (2)

Publication Number Publication Date
CA2309154A1 true CA2309154A1 (en) 1999-05-14
CA2309154C CA2309154C (en) 2010-02-16

Family

ID=22053669

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2309154A Expired - Lifetime CA2309154C (en) 1997-11-03 1998-11-03 Substituted porphyrins

Country Status (10)

Country Link
US (4) US6916799B2 (en)
EP (1) EP1045851B1 (en)
JP (2) JP2001521939A (en)
AT (1) ATE238307T1 (en)
AU (1) AU737650B2 (en)
CA (1) CA2309154C (en)
DE (1) DE69813898T2 (en)
ES (1) ES2198767T3 (en)
IL (1) IL135949A0 (en)
WO (1) WO1999023097A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
ES2198767T3 (en) * 1997-11-03 2004-02-01 Duke University REPLACED PORPHIRINS.
JP4648542B2 (en) 1998-04-24 2011-03-09 デューク ユニバーシティ Substituted porphyrin
WO2000023568A2 (en) * 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
MXPA01007451A (en) * 1999-01-25 2004-03-10 Nat Jewish Med & Res Center Substituted porphyrins.
FR2806911B1 (en) * 2000-03-28 2003-01-10 Univ Rene Descartes USE OF SOD MIMETICS IN THE TREATMENT OF HEPATOCELLULAR DEFICIENCIES
DK1392328T3 (en) * 2001-01-19 2009-11-09 Nat Jewish Health Medication for protection in radiotherapy
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
EP1439842A4 (en) 2001-06-01 2009-09-02 Nat Jewish Med & Res Center Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
ATE422944T1 (en) * 2001-12-14 2009-03-15 Alcon Inc SUPEROXIDE DISMUTAS MIMETICS FOR THE TREATMENT OF EYE DISEASES
EP1513537A4 (en) * 2002-06-07 2006-09-06 Univ Duke Substituted porphyrins
MXPA05005240A (en) * 2002-12-06 2005-07-25 Alcon Inc Superoxide dismutase mimics for the treatment of ocular disorders and diseases.
MXPA05005937A (en) * 2002-12-06 2005-08-18 Alcon Inc Histone deacetylase inhibitors for treating degenerative diseases of the eye.
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
NL1022597C2 (en) * 2003-02-05 2004-08-06 Photobiochem N V Use of a photosensitizer compound for the preparation of a pharmaceutical preparation, a method for preparing a pharmaceutical preparation and a method for treating a mammal.
JP4741205B2 (en) * 2003-07-07 2011-08-03 真 湯浅 Metalloporphyrin complex-embedded liposome, method for producing the same, and medicament using the same
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
EP1718201B1 (en) 2004-02-09 2016-09-14 Duke University Substituted porphyrins
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
KR20060135922A (en) 2004-03-29 2006-12-29 이노텍 파마슈티컬스 코포레이션 Pyridyl-substituted porphyrin compounds and methods of use thereof
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
WO2007038630A2 (en) * 2005-09-28 2007-04-05 Inotek Pharmaceuticals Corporation N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US9855279B2 (en) 2006-10-12 2018-01-02 Galera Labs, Llc Methods of treating oral mucositis
US20080289053A1 (en) * 2007-05-15 2008-11-20 The Regents Of The University Of California Methods and systems for identifying modulators of longevity
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
ES2600469T3 (en) * 2008-05-23 2017-02-09 National Jewish Health A compound for use in the treatment of lesions associated with exposure to phosgene gas or chlorine gas
US8608950B2 (en) * 2009-12-30 2013-12-17 Uop Llc Process for removing metals from resid
PL2625180T3 (en) * 2010-10-06 2016-10-31 Porphyrin treatment of neurodegenerative diseases
JP5823988B2 (en) * 2011-01-31 2015-11-25 国立大学法人宇都宮大学 Method for producing metal complex of compound having porphyrin type skeleton
US9149483B2 (en) 2011-09-26 2015-10-06 Galera Labs, Llc Methods for treatment of diseases
MX2014006255A (en) 2011-12-02 2015-04-10 Univ Colorado Regents Metalloporphyrin neurological treatments.
WO2015034777A1 (en) 2013-09-03 2015-03-12 Biomimetix J.V., Llc Methods of treating biofilms
CN105899132B (en) 2013-12-31 2020-02-18 雅培糖尿病护理公司 Self-powered analyte sensor and devices using same
US10064871B2 (en) 2014-01-22 2018-09-04 Biomimetix Jv, Llc Methods of treating skin disorders
WO2015112586A1 (en) 2014-01-22 2015-07-30 Duke University Methods of treating pruritus
JP7041959B2 (en) 2015-08-11 2022-03-25 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー Pentaaza macrocyclic ring complex with oral bioavailability
WO2018237249A1 (en) * 2017-06-22 2018-12-27 Biomimetix Jv, Llc Methods, compositions, and kits for treating inflammatory skin conditions
US11918549B2 (en) 2017-08-25 2024-03-05 AZ Solutions LLC System and method for wound treatment and irrigation
EP3687551A4 (en) 2017-09-29 2021-06-23 Duke University Fluoro substituted porphyrin compounds, pharmaceutical compositions comprising the same, and methods of preparing and using the same
EA201992431A1 (en) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи COMBINED CANCER IMMUNOTHERAPY USING PENTA-ASA-MACROCYCLIC RING COMPLEX
CN111100133B (en) * 2019-12-30 2020-12-01 云南大学 Metalloporphyrin compound and preparation method and application thereof
WO2022235781A1 (en) * 2021-05-04 2022-11-10 AZ solutions, LLC Treatment of lung and airway diseases and disorders

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2951799A (en) 1957-11-13 1960-09-06 Monsanto Chemicals Photoxidation processes using heterocyclic photosensitizers
DE3464252D1 (en) 1983-06-03 1987-07-23 Hoffmann La Roche Labelled molecules for fluorescence immunoassays and processes and intermediates for their preparation
US4829984A (en) 1983-12-15 1989-05-16 Gordon Robert T Method for the improvement of transplantation techniques and for the preservation of tissue
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5087438A (en) 1984-07-03 1992-02-11 Gordon Robert T Method for affecting intracellular and extracellular electric and magnetic dipoles
GB8429845D0 (en) 1984-11-26 1985-01-03 Efamol Ltd Porphyrins & cancer treatment
US4758422A (en) 1985-01-04 1988-07-19 Salutar Inc. Ferrioxamine paramagnetic contrast agents for MR imaging
US4657902A (en) 1985-03-25 1987-04-14 The Rockefeller University Therapeutic use of tin mesoporphyrin
ATE78158T1 (en) 1985-05-22 1992-08-15 Liposome Technology Inc METHOD AND SYSTEM FOR INHALATION OF LIPOSOMES.
US5248603A (en) 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
DK402785D0 (en) 1985-09-03 1985-09-03 Syn Tek Ab PROCEDURE FOR THE PREPARATION OF AN ENZYM
US4866054A (en) 1986-05-13 1989-09-12 Chai-Tech Corporation Antioxidant metallo-organic treatment of inflammation
US4746735A (en) 1986-11-21 1988-05-24 The Dow Chemical Company Regiospecific aryl nitration of meso-substituted tetraarylporphyrins
US5162231A (en) 1989-10-25 1992-11-10 Cole Dean A Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung
EP0676472A1 (en) 1987-03-14 1995-10-11 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Human manganese superoxide dismutase (hMn-SOD)
US5223538A (en) 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
US5227405A (en) 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
US4892941A (en) 1987-04-17 1990-01-09 Dolphin David H Porphyrins
US4851403A (en) 1987-04-21 1989-07-25 Johnson Matthey, Inc. Radiation sensitizers
US4885114A (en) 1987-04-22 1989-12-05 Barnes Engineering Co. Metallized tetra((meso)-5-methyl-2-thiophene)porphines, platinum (5-bromo octaethylporphine) and optical filters containing same
US5051337A (en) 1987-06-10 1991-09-24 Director-General Of Agency Of Industrial Science And Technology Optical recording material
GB8805849D0 (en) 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
US5162519A (en) 1988-03-11 1992-11-10 Efamol Holdings Plc Porphyrins and cancer treatment
DE3809671A1 (en) 1988-03-18 1989-09-28 Schering Ag PORPHYRINE COMPLEX COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM
US5284647A (en) 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
US5192788A (en) 1988-05-23 1993-03-09 Georgia State University Foundation, Inc. Porphyrin antiviral compositions
US5109016A (en) 1988-05-23 1992-04-28 Georgia State University Foundation, Inc. Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions
FR2632187B1 (en) 1988-06-02 1990-09-14 Centre Nat Rech Scient METALLOPORPHYRIN DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION AND THEIR USE FOR THE PREPARATION OF HYBRID MOLECULES
US5171680A (en) 1988-06-14 1992-12-15 Chiron Corporation Superoxide dismutase analogs having novel binding properties
EP0414915B1 (en) 1989-03-06 1996-06-12 Suntory Limited New superoxide dismutase
JPH0341441A (en) * 1989-07-07 1991-02-21 Konica Corp Silver halide photographic sensitive material improved in spot fault
DK455789D0 (en) 1989-09-15 1989-09-15 Symbicom Ab POLYPEPTIDE
US5010073A (en) 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
EP0424033A3 (en) 1989-10-19 1991-07-31 Pola Chemical Industries Inc External skin preparation
US5236915A (en) 1990-05-31 1993-08-17 Health Research, Inc. Meso poly(4-sulfonatophenyl) porphines as MRI image enhancing agents
EP0462836A3 (en) 1990-06-20 1992-08-26 Mitsui Toatsu Chemicals, Inc. Recombinant vector plasmid capable of expressing human manganese superoxide dismutase, and process of producing this enzyme
US5202317A (en) 1990-09-13 1993-04-13 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
US5217966A (en) 1990-09-13 1993-06-08 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
AU8947791A (en) 1990-11-01 1992-05-26 Scripps Research Institute, The Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
EP0557417A4 (en) 1990-11-14 1994-06-08 Uab Research Foundation Compositions for reducing oxidative injury
US5192757A (en) 1990-12-20 1993-03-09 Glaxo Inc. Cobalt porphyrins
GB9103991D0 (en) 1991-02-26 1991-04-10 Nat Res Dev Molecular electronic devices
FR2676738B1 (en) 1991-05-22 1995-05-05 Ir2M NOVEL ORGANIC TRANSITION METAL WITH PORPHYRINIC STRUCTURE, THERAPEUTIC COMPOSITION CONTAINING SAME, IN PARTICULAR WITH HYPOGLYCEMIC ACTIVITY.
WO1993002090A1 (en) 1991-07-19 1993-02-04 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5262532A (en) 1991-07-22 1993-11-16 E.R. Squibb & Sons, Inc. Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging
US5212300A (en) 1991-09-12 1993-05-18 Sun Company, Inc. (R&M) Cyano- and polycyanometallo-porphyrins as catalysts for alkane oxidation
US6011146A (en) 1991-11-15 2000-01-04 Institut Pasteur Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US5493017A (en) 1992-08-14 1996-02-20 The Trustees Of The University Of Pennsylvania Ring-metalated porphyrins
US5599924A (en) 1992-08-14 1997-02-04 Trustees Of The University Of Pennsylvania Electron-deficient porphyrins and processes and intermediates for preparing same
US5371199B1 (en) 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor
EP0658109B1 (en) 1992-09-03 2001-05-30 The Regents Of The University Of California Metallo porphyrin compositions
US5696109A (en) 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5403834A (en) 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5834509A (en) 1992-12-07 1998-11-10 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
DE4305523A1 (en) 1993-02-17 1994-08-18 Diagnostikforschung Inst Meso-tetraphenylporphyrin complexes, processes for their preparation and pharmaceutical compositions containing them
US6417182B1 (en) 1993-08-25 2002-07-09 Anormed Inc. Pharmaceutical compositions comprising metal complexes
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US5608054A (en) 1993-12-29 1997-03-04 Sun Company, Inc. (R&M) Porphyrins and metal complexes thereof having haloalkyl side chains
US5405369A (en) 1994-01-25 1995-04-11 Medical College Of Ohio Photochemical ablation of gastro-intestinal tissue for augmentation of an organ
US5604199A (en) 1994-03-29 1997-02-18 The Nemours Foundation Method of treating fibrosis in skeletal muscle tissue
HUT76327A (en) 1994-05-13 1997-08-28 Monsanto Co Pharmaceutical compositions catalyzing decomposition of peroxy-nitrite
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
US5563132A (en) 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
FR2723694B1 (en) * 1994-08-19 1996-09-27 Oreal USE OF SALTS OF CATIONIC PORPHINE DERIVATIVES AS PHOTOSENSITIZERS OF GRAM-NEGATIVE BACTERIA
AU3758695A (en) 1994-09-20 1996-04-09 Duke University Oxidoreductase activity of manganic porphyrins
CA2132690A1 (en) 1994-09-22 1996-03-23 Dean Willis Control and modulation of inflammatory response in humans in need of such control and modulation
US6013241A (en) 1995-01-23 2000-01-11 Schering Aktiengesellschaft Use of porphyrin-complex or expanded porphyrin-complex compounds as an infarction localization diagnosticum
DE69635304T2 (en) * 1995-06-07 2006-07-20 Duke University FAENGER FOR OXIDANTS
WO1997006831A1 (en) 1995-08-17 1997-02-27 Monsanto Company Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
US5648523A (en) 1995-10-26 1997-07-15 Chiang Long Y Fullerene derivatives as free-radical scavengers
US5948771A (en) 1996-01-31 1999-09-07 The Trustees Of Columbia University In The City Of New York Method for treating heart failure using tetrapyrroles and metallotetrapyrroles
US5756492A (en) 1996-09-09 1998-05-26 Sangstat Medical Corporation Graft survival prolongation with porphyrins
CA2283057A1 (en) * 1997-02-05 1998-08-06 Board Of Regents, The University Of Texas System Porphyrin compounds as telomerase inhibitors
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
ES2198767T3 (en) * 1997-11-03 2004-02-01 Duke University REPLACED PORPHIRINS.
MXPA01007451A (en) * 1999-01-25 2004-03-10 Nat Jewish Med & Res Center Substituted porphyrins.
US6608050B2 (en) 1999-07-20 2003-08-19 Pharmacia & Upjohn Company Lyophilizate of lipid complex of water insoluble porphyrins
AU1087401A (en) 1999-10-13 2001-04-23 Uab Research Foundation Metalloporphyrin treatment of neurologic disease
US6548045B2 (en) * 1999-11-30 2003-04-15 Photochemical Co., Ltd. Nitroimidazole substituted porphyrin complex
JP3383839B2 (en) * 2000-03-13 2003-03-10 奈良先端科学技術大学院大学長 Novel mercapto-substituted imidazolyl porphyrin metal complex monomer, polymer having the same as a repeating unit, and methods for producing them
US6624187B1 (en) * 2000-06-12 2003-09-23 Health Research, Inc. Long wave length absorbing bacteriochlorin alkyl ether analogs
US6403788B1 (en) 2000-07-11 2002-06-11 Eukarion, Inc. Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species
US6573258B2 (en) * 2000-09-27 2003-06-03 Frontier Scientific, Inc. Photodynamic porphyrin antimicrobial agents
US6566517B2 (en) * 2001-06-06 2003-05-20 Brookhaven Science Associates, Llc Metalloporphyrins and their uses as imageable tumor-targeting agents for radiation therapy

Also Published As

Publication number Publication date
DE69813898D1 (en) 2003-05-28
US20060074062A1 (en) 2006-04-06
ES2198767T3 (en) 2004-02-01
IL135949A0 (en) 2001-05-20
JP2001521939A (en) 2001-11-13
US20070179124A1 (en) 2007-08-02
ATE238307T1 (en) 2003-05-15
EP1045851B1 (en) 2003-04-23
AU737650B2 (en) 2001-08-23
JP2010229145A (en) 2010-10-14
EP1045851A4 (en) 2001-05-09
DE69813898T2 (en) 2004-03-11
US6916799B2 (en) 2005-07-12
US20080113956A1 (en) 2008-05-15
CA2309154C (en) 2010-02-16
US20020042407A1 (en) 2002-04-11
WO1999023097A1 (en) 1999-05-14
AU1297999A (en) 1999-05-24
EP1045851A1 (en) 2000-10-25
JP5312404B2 (en) 2013-10-09

Similar Documents

Publication Publication Date Title
CA2309154A1 (en) Substituted porphyrins
CA2329751A1 (en) Substituted porphyrins
CA2669481A1 (en) Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels
CA2153979A1 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
CA2131683A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
JP2002512989A5 (en)
CA2303934A1 (en) Tetrazole-containing rapamycin analogs with shortened half-lives
JP2004531544A5 (en)
CA2504730A1 (en) Cephem compounds
CA2283520A1 (en) Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
CA2189603A1 (en) Propiophenone derivative and processes for preparing the same
CA2420996A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
IT8449031A1 (en) USE OF METHYLOL TRANSFER COMPOUNDS IN THERAPY RELATED PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR PREPARING THESE
CA2297011A1 (en) Sulfonamide derivatives as therapeutic or prophylactic agent for glomerulopathy
CA2087540A1 (en) Composition, method and kit for potentiating antitumor activity and for curing tumor
CA2223407A1 (en) Oxidant scavengers
ZA959444B (en) Polyanionic benzylglycosides as inhibitors of smooth muscle cell proliferation.
CA2014545A1 (en) Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
AU552322B2 (en) Substituted imidazoles
CA2356320A1 (en) Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
CA2210492A1 (en) Neuraminic acid derivatives, their preparation and their medical use
CA2378456A1 (en) Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
CA2192555A1 (en) 2-acylaminopropanol compound and medicinal composition
MXPA02001571A (en) Method of cancer treatment.
KR960703586A (en) Photosensitizers

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20181105